Michael J Parnham
Overview
Explore the profile of Michael J Parnham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asbjarnarson A, Joelsson J, Gardarsson F, Sigurdsson S, Parnham M, Kricker J, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076911
The respiratory epithelium maintains the barrier against inhaled harmful agents. When barrier failure occurs, as in several respiratory diseases, acute or chronic inflammation leading to destructive effects and exacerbations can...
2.
Schiffmann S, Henke M, Brunner S, Bennett A, Yagubi Y, Magari F, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39518983
Pateamines act as inhibitors of the RNA helicase eIF4A and exhibit antiviral and anticancer properties. Recently, we observed that inhibition of eIF4A by rocaglates affects the immune response. To investigate...
3.
Becker A, Rohrich K, Leske A, Heinicke U, Knape T, Kannt A, et al.
Immunotargets Ther
. 2024 Nov;
13:595-616.
PMID: 39507298
Background: COVID-19 is a serious viral infection, which is often associated with a lethal outcome. Therefore, understanding mechanisms, which affect the immune response during SARS-CoV2 infection, are important. Methods: To...
4.
Parnham M
Inflammopharmacology
. 2024 Jun;
32(4):2253-2283.
PMID: 38878142
This article is an autobiographical account of a research career in inflammatory diseases, mechanisms and pharmacotherapy, drug research and development, in academia and industry in various European countries spanning the...
5.
Roser L, Sakellariou C, Lindstedt M, Neuhaus V, Dehmel S, Sommer C, et al.
J Immunotoxicol
. 2024 Apr;
21(1):2332177.
PMID: 38578203
Drug-induced hepatotoxicity constitutes a major reason for non-approval and post-marketing withdrawal of pharmaceuticals. In many cases, preclinical models lack predictive capacity for hepatic damage in humans. A vital concern is...
6.
Roser L, Luckhardt S, Ziegler N, Thomas D, Wagner P, Damm G, et al.
Front Immunol
. 2023 Dec;
14:1275368.
PMID: 38045689
Introduction: Hepatotoxicity induced by immunotherapeutics is an appearing cause for immune-mediated drug-induced liver injury. Such immuno-toxic mechanisms are difficult to assess using current preclinical models and the incidence is too...
7.
Parnham M, Norris V, Kricker J, Gudjonsson T, Page C
Adv Pharmacol
. 2023 Jul;
98:83-110.
PMID: 37524493
Macrolide compounds, many of which are derived from natural sources, all share a lactone ring structure, but of varying sizes. Their biological activities differ with structure and size but tend...
8.
Schiffmann S, Henke M, Seifert M, Ulshofer T, Roser L, Magari F, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982945
A promising new approach to broad spectrum antiviral drugs is the inhibition of the eukaryotic translation initiation factor 4A (elF4A), a DEAD-box RNA helicase that effectively reduces the replication of...
9.
Schiffmann S, Gunne S, Ulshofer T, Henke M, Roser L, Schneider A, et al.
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145307
We characterized the in vitro safety and bioavailability profile of silvestrol, a compound effective against various viruses, such as corona- and Ebolaviruses, with an EC value of about 5 nM....
10.
Nieraad H, de Bruin N, Arne O, Hofmann M, Pannwitz N, Resch E, et al.
Front Aging Neurosci
. 2022 May;
14:876826.
PMID: 35572151
A causal contribution of hyperhomocysteinemia to cognitive decline and Alzheimer's disease (AD), as well as potential prevention or mitigation of the pathology by dietary intervention, have frequently been subjects of...